The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients

Trial Profile

The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Sep 2014 According to the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
    • 19 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top